Abstract OT2-19-08: Phase IB/II trial of palbociclib and binimetinib in advanced triple-negative breast cancer with hyperactivation of ERK and/or CDK4/6
Luís Manso(Research Institute Hospital 12 de Octubre), Miguel Quintela-Fandiño(Spanish National Cancer Research Centre), Juan Miguel Cejalvo(Universitat de València), José Á. García-Sáenz(Hospital Clínico San Carlos), Juan Antonio Guerra(Hospital Universitario de Fuenlabrada), Silvana Mourón(Spanish National Cancer Research Centre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Rámón Colomer(Hospital Universitario de La Princesa), Alfonso Cortés(Hospital Universitario Ramón y Cajal), Serafín Morales(Hospital Universitari Arnau de Vilanova), Eduardo Caleiras(Spanish National Cancer Research Centre), Jorge Silva(University of Lisbon), Diego Malón(Hospital Universitario de Fuenlabrada)
Cited by 1
Related Papers
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268